Article title: Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
Authors: Liv Solvår Nymark, Jacob Dag Berild, Trude Marie Lyngstad, Brita Askeland Winje, Didrik Frimann Vestrheim, Ingeborg Aaberge, Lene Kristine Juvet & Ellen Wolff
Journal: Human Vaccines & Immunotherapeutics
Bibliometrics: Volume 18, Number 1, pages e2101333-1 - e2101333-9
DOI: http://dx.doi.org/10.1080/21645515.2022.2101333
After publication, a reporting error in was noted, but due to changes in the pricing and mortality data, additional corrections were required to the article text and . The conclusions presented in the article remain unchanged.
Table 3. Overview of model input parameters.
Table 4. Estimated number of Norwegian cases of (invasive pneumococcal disease (IPD) and non-invasive pneumococcal community-acquired pneumonia (PnCAP) in the epidemiological model, with and without vaccination with 23-valent polysaccharide vaccine (PVV23), depending on age and year after vaccination, given the input parameters in Table 2, and 75% vaccination coverage.
Table 5. Base case results (NOK/EUR) – at 75% vaccination coverage.
Table 6. Sensitivity analyses results (NOK/EUR) – varying the price of PVV23 with 25%, 50%, 75% rebate – at 75% vaccination coverage.
Table 7. Sensitivity analyses results (NOK/EUR) – varying the price of PCV13 with 25%, 50%, 75% rebate – at 75% vaccination coverage and changing VE data.